4//SEC Filing
Fotopoulos Alexandros 4
Accession 0001209191-22-058795
CIK 0001787297other
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 4:15 PM ET
Size
10.1 KB
Accession
0001209191-22-058795
Insider Transaction Report
Form 4
Fotopoulos Alexandros
Chief Technical Officer
Transactions
- Exercise/Conversion
Common Stock
2022-11-22+12,500→ 23,965 total - Sale
Common Stock
2022-11-22$1.33/sh−3,720$4,948→ 20,245 total - Exercise/Conversion
Restricted Stock Units
2022-11-22−12,500→ 37,500 total→ Common Stock (12,500 underlying)
Footnotes (6)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- [F2]The reported total includes 3,082 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
- [F3]The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
- [F4]The reported transaction represents the settlement of restricted stock units which vested on June 15, 2022 but for which settlement was delayed due to an inadvertent administrative error.
- [F5]1/4 of the RSUs vested on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- [F6]These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
Documents
Issuer
Passage BIO, Inc.
CIK 0001787297
Entity typeother
Related Parties
1- filerCIK 0001799814
Filing Metadata
- Form type
- 4
- Filed
- Nov 24, 7:00 PM ET
- Accepted
- Nov 25, 4:15 PM ET
- Size
- 10.1 KB